Myriad Genetics, Inc. (0K3W.L)
USD 14.11
(0.53%)
USD 14.11
(0.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 88.1 Million USD | 153.04% |
| 2021 | -166.1 Million USD | -41.97% |
| 2020 | -117 Million USD | -183.39% |
| 2019 | 140.3 Million USD | 0.0% |
| 2018 | 140.3 Million USD | 238.09% |
| 2017 | -101.6 Million USD | -2978.79% |
| 2016 | -3.3 Million USD | 95.18% |
| 2015 | -68.5 Million USD | -6.86% |
| 2014 | -64.1 Million USD | 1.11% |
| 2013 | -64.82 Million USD | 37.72% |
| 2012 | -104.07 Million USD | -20.52% |
| 2011 | -86.35 Million USD | -63.91% |
| 2010 | -52.68 Million USD | 43.26% |
| 2009 | -92.84 Million USD | -46.18% |
| 2008 | -63.51 Million USD | 73.29% |
| 2007 | -237.73 Million USD | -65.75% |
| 2006 | -143.43 Million USD | -45.51% |
| 2005 | -98.57 Million USD | -99.1% |
| 2004 | -49.5 Million USD | 41.05% |
| 2003 | -83.98 Million USD | -36.33% |
| 2002 | -61.6 Million USD | -0.88% |
| 2001 | -61.06 Million USD | -69.93% |
| 2000 | -35.93 Million USD | 36.07% |
| 1999 | -56.21 Million USD | -941.01% |
| 1998 | -5.4 Million USD | 62.76% |
| 1997 | -14.5 Million USD | 5.23% |
| 1996 | -15.3 Million USD | -23.39% |
| 1995 | -12.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 108 Million USD | 22.59% |
| 2023 Q3 | 125.4 Million USD | 24.16% |
| 2023 Q2 | 101 Million USD | -6.48% |
| 2022 Q4 | 88.1 Million USD | 231.2% |
| 2022 Q1 | -75.3 Million USD | 54.67% |
| 2022 Q3 | 26.6 Million USD | 691.11% |
| 2022 Q2 | -4.5 Million USD | 94.02% |
| 2022 FY | 88.1 Million USD | 153.04% |
| 2021 FY | -166.1 Million USD | -41.97% |
| 2021 Q2 | 82.3 Million USD | 20.15% |
| 2021 Q3 | -201.7 Million USD | -345.08% |
| 2021 Q4 | -166.1 Million USD | 17.65% |
| 2021 Q1 | 68.5 Million USD | -60.17% |
| 2020 Q1 | 173 Million USD | -19.68% |
| 2020 Q3 | 173.4 Million USD | 32.27% |
| 2020 Q2 | 131.1 Million USD | -24.22% |
| 2020 FY | -117 Million USD | -183.39% |
| 2020 Q4 | 172 Million USD | -0.81% |
| 2019 Q4 | 215.4 Million USD | 2.23% |
| 2019 Q2 | 140.3 Million USD | -21.4% |
| 2019 FY | 140.3 Million USD | 0.0% |
| 2019 Q1 | 178.5 Million USD | -2.3% |
| 2019 Q3 | 210.7 Million USD | 50.18% |
| 2018 FY | 140.3 Million USD | 238.09% |
| 2018 Q1 | -28.1 Million USD | 38.24% |
| 2018 Q2 | -101.6 Million USD | -261.57% |
| 2018 Q3 | 164.7 Million USD | 262.11% |
| 2018 Q4 | 182.7 Million USD | 10.93% |
| 2017 Q4 | -45.5 Million USD | -227.34% |
| 2017 FY | -101.6 Million USD | -2978.79% |
| 2017 Q3 | -13.9 Million USD | -321.21% |
| 2017 Q2 | -3.3 Million USD | -107.62% |
| 2017 Q1 | 43.3 Million USD | -54.85% |
| 2016 Q2 | -68.5 Million USD | 43.15% |
| 2016 FY | -3.3 Million USD | 95.18% |
| 2016 Q4 | 95.9 Million USD | -14.6% |
| 2016 Q1 | -120.5 Million USD | 10.54% |
| 2016 Q3 | 112.3 Million USD | 263.94% |
| 2015 FY | -68.5 Million USD | -6.86% |
| 2015 Q3 | -87.4 Million USD | -36.35% |
| 2015 Q4 | -134.7 Million USD | -54.12% |
| 2015 Q2 | -64.1 Million USD | -16.1% |
| 2015 Q1 | -55.2 Million USD | 7.54% |
| 2014 Q1 | -85.79 Million USD | -19.83% |
| 2014 Q4 | -59.7 Million USD | 14.46% |
| 2014 Q2 | -64.82 Million USD | 24.45% |
| 2014 FY | -64.1 Million USD | 1.11% |
| 2014 Q3 | -69.8 Million USD | -7.69% |
| 2013 Q1 | -112.32 Million USD | -64.16% |
| 2013 Q4 | -71.59 Million USD | 15.75% |
| 2013 Q3 | -84.98 Million USD | 18.34% |
| 2013 Q2 | -104.07 Million USD | 7.34% |
| 2013 FY | -64.82 Million USD | 37.72% |
| 2012 FY | -104.07 Million USD | -20.52% |
| 2012 Q4 | -68.42 Million USD | 28.42% |
| 2012 Q1 | -104.85 Million USD | 3.67% |
| 2012 Q2 | -86.35 Million USD | 17.64% |
| 2012 Q3 | -95.58 Million USD | -10.69% |
| 2011 Q2 | -52.68 Million USD | 21.81% |
| 2011 FY | -86.35 Million USD | -63.91% |
| 2011 Q4 | -108.84 Million USD | -73.67% |
| 2011 Q3 | -62.67 Million USD | -18.97% |
| 2011 Q1 | -67.37 Million USD | 0.43% |
| 2010 Q3 | -123.3 Million USD | -32.81% |
| 2010 Q4 | -67.66 Million USD | 45.12% |
| 2010 FY | -52.68 Million USD | 43.26% |
| 2010 Q1 | -102.14 Million USD | -69.03% |
| 2010 Q2 | -92.84 Million USD | 9.11% |
| 2009 Q1 | -200.68 Million USD | -12.12% |
| 2009 Q4 | -60.43 Million USD | 33.74% |
| 2009 Q2 | -63.51 Million USD | 68.35% |
| 2009 FY | -92.84 Million USD | -46.18% |
| 2009 Q3 | -91.19 Million USD | -43.59% |
| 2008 Q2 | -237.73 Million USD | -66.96% |
| 2008 Q4 | -178.98 Million USD | 22.26% |
| 2008 FY | -63.51 Million USD | 73.29% |
| 2008 Q1 | -142.39 Million USD | -24.28% |
| 2008 Q3 | -230.23 Million USD | 3.16% |
| 2007 Q4 | -114.57 Million USD | -6.86% |
| 2007 Q1 | -194.87 Million USD | -126.94% |
| 2007 FY | -237.73 Million USD | -65.75% |
| 2007 Q2 | -143.43 Million USD | 26.4% |
| 2007 Q3 | -107.21 Million USD | 25.25% |
| 2006 Q4 | -85.86 Million USD | 3.11% |
| 2006 FY | -143.43 Million USD | -45.51% |
| 2006 Q3 | -88.62 Million USD | 10.09% |
| 2006 Q1 | -106.4 Million USD | 10.27% |
| 2006 Q2 | -98.57 Million USD | 7.36% |
| 2005 Q3 | -38.72 Million USD | 21.78% |
| 2005 FY | -98.57 Million USD | -99.1% |
| 2005 Q1 | -48.39 Million USD | 22.59% |
| 2005 Q2 | -49.5 Million USD | -2.31% |
| 2005 Q4 | -118.58 Million USD | -206.19% |
| 2004 Q4 | -62.51 Million USD | 4.55% |
| 2004 Q2 | -83.98 Million USD | -79.02% |
| 2004 FY | -49.5 Million USD | 41.05% |
| 2004 Q3 | -65.49 Million USD | 22.02% |
| 2004 Q1 | -46.91 Million USD | -10.47% |
| 2003 Q1 | -80.42 Million USD | 17.11% |
| 2003 Q4 | -42.46 Million USD | 11.96% |
| 2003 Q3 | -48.23 Million USD | 21.7% |
| 2003 Q2 | -61.6 Million USD | 23.4% |
| 2003 FY | -83.98 Million USD | -36.33% |
| 2002 FY | -61.6 Million USD | -0.88% |
| 2002 Q2 | -61.06 Million USD | -4.27% |
| 2002 Q3 | -48.51 Million USD | 20.55% |
| 2002 Q1 | -58.56 Million USD | -10.08% |
| 2002 Q4 | -97.02 Million USD | -99.98% |
| 2001 Q3 | -47.35 Million USD | -31.78% |
| 2001 Q1 | -96.2 Million USD | -4.08% |
| 2001 Q2 | -35.93 Million USD | 62.64% |
| 2001 Q4 | -53.2 Million USD | -12.35% |
| 2001 FY | -61.06 Million USD | -69.93% |
| 2000 Q3 | -58.63 Million USD | -4.3% |
| 2000 Q4 | -92.42 Million USD | -57.64% |
| 2000 Q2 | -56.21 Million USD | -95.33% |
| 2000 Q1 | -28.78 Million USD | -3.9% |
| 2000 FY | -35.93 Million USD | 36.07% |
| 1999 Q2 | -5.4 Million USD | 34.94% |
| 1999 Q4 | -27.7 Million USD | -76.43% |
| 1999 Q3 | -15.7 Million USD | -190.74% |
| 1999 FY | -56.21 Million USD | -941.01% |
| 1999 Q1 | -8.3 Million USD | 52.02% |
| 1998 Q3 | -9.2 Million USD | 36.55% |
| 1998 FY | -5.4 Million USD | 62.76% |
| 1998 Q4 | -17.3 Million USD | -88.04% |
| 1998 Q1 | -13.2 Million USD | 20.96% |
| 1998 Q2 | -14.5 Million USD | -9.85% |
| 1997 Q3 | -20 Million USD | -30.72% |
| 1997 FY | -14.5 Million USD | 5.23% |
| 1997 Q4 | -16.7 Million USD | 16.5% |
| 1997 Q1 | -16.2 Million USD | -10.2% |
| 1997 Q2 | -15.3 Million USD | 5.56% |
| 1996 Q2 | -12.4 Million USD | 51.18% |
| 1996 Q1 | -25.4 Million USD | 8.3% |
| 1996 FY | -15.3 Million USD | -23.39% |
| 1996 Q4 | -14.7 Million USD | -4.26% |
| 1996 Q3 | -14.1 Million USD | -13.71% |
| 1995 Q4 | -27.7 Million USD | 0.0% |
| 1995 FY | -12.4 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 201.13% |
| Dynavax Technologies Corporation | 106.63 Million USD | 17.382% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 362.773% |
| Perrigo Company plc | 3.32 Billion USD | 97.348% |
| Illumina, Inc. | 1.21 Billion USD | 92.743% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.672% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 177.357% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 98.93% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.315% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 39.273% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 425.092% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1125.824% |
| Waters Corporation | 1.96 Billion USD | 95.506% |
| Biogen Inc. | 6.28 Billion USD | 98.599% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 1340.845% |
| Evolus, Inc. | 63.7 Million USD | -38.287% |
| Adicet Bio, Inc. | -142 Million USD | 162.039% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1077.152% |
| bluebird bio, Inc. | 108.57 Million USD | 18.855% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 80.794% |
| FibroGen, Inc. | 56.76 Million USD | -55.196% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 92.306% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1164.338% |
| Homology Medicines, Inc. | 18.43 Million USD | -377.843% |
| Geron Corporation | 14.76 Million USD | -496.843% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 94.443% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 55.52% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 262.378% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 179.083% |
| Zoetis Inc. | 4.76 Billion USD | 98.15% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 974.789% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 95.801% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 76.739% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.921% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 704.584% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 91.644% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -176.305% |
| Verastem, Inc. | -37.27 Million USD | 336.332% |
| Nektar Therapeutics | 210.24 Million USD | 58.096% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 144.089% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 339.376% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 90.902% |
| OPKO Health, Inc. | 230.68 Million USD | 61.809% |
| Exelixis, Inc. | -73.05 Million USD | 220.602% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 50.31% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 165.066% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 158.335% |
| uniQure N.V. | -102.95 Million USD | 185.575% |
| Imunon, Inc. | -4.69 Million USD | 1974.758% |
| Blueprint Medicines Corporation | 702.83 Million USD | 87.465% |
| Insmed Incorporated | 721.62 Million USD | 87.791% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 93.62% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 382.218% |
| TG Therapeutics, Inc. | 17.86 Million USD | -393.226% |
| Incyte Corporation | -3.17 Billion USD | 102.775% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 88.496% |